Keep up to date
Press release | 19.03.2020
Univercells investit à Jumet pour la production de vaccins à large échelle
Avec une capacité de 15 000 m², ce nouveau site permettra à Univercells d’accélérer le développement et la production commerciale ...
Press release | 18.02.2020
Univercells secures up to €50M investment from KKR platform to speed delivery of manufacturing technologies
Univercells has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment ...
Press release | 03.10.2019
Univercells boosted by EUR 20M European financing to accelerate the delivery of its vaccine portfolio
Financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable ...
Univercells news | 10.07.2019
Univercells expands its development capacity with modular laboratories
400 m² extension will enable the company to pursue the development of its viral vaccines' portfolio addressing global health challenges
Press release | 13.06.2019
Univercells granted $14.3M to deliver affordable measles & rubella vaccines
Univercells announces today second grant from the Bill & Melinda Gates Foundation to develop a cost-effective manufacturing process and proceed ...
Univercells news | 17.04.2019
Introducing the scale-X™ carbo bioreactor system
The scale-X™ carbo is a bench-scale automated cell culture system for expression and concentration of viral drug substance, suited for ...
In the press | 01.04.2019
Reinventing the Biomanufacturing Wheel
Our Product Manager Tania explains the challenges in biologic manufacturing and Univercells' solutions in BioParhm International article
Univercells news | 27.03.2019
Univercells joins the Belgian State Visit to South Korea
Belgian State Visit to Korea - Hugues Bultot, CEO of Univercells, joins the Belgian business delegation to strengthen and further ...